Global Stent Grafts Market 2017- Medtronic, Gore, Endologix and Cook Medical

Global Stent Grafts Market 2017-2022:

Global Stent Grafts market Report offers decisive insights into the overall Stent Grafts industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Stent Grafts industry segments based on the type of applications, type of product Components and services, and different geographical regions.

At First, the research study provides exquisite knowledge of the global Stent Grafts market structure, valuates and outlines its variable aspects & applications.

Further, Stent Grafts market report along with computable information, qualitative information sets and evaluation tools are provided in this study for improved Stent Grafts analysis of the overall market scenario and future prospects. Information such as Stent Grafts industry predilection insights and drivers, challenges and fortuity assists the readers for understanding the current trends in the global Stent Grafts market. Tools such as market positioning of Stent Grafts key players and tempting investment scheme provide the readers with perception on the competitive scenario of the worldwide Stent Grafts market. This Stent Grafts report concludes with company profiles section that points out major data about the vital players involved in global Stent Grafts industry.

Do Inquiry Before Accessing 2017-2022 Global Stent Grafts Market Report at

In order to help key decision makers, the Stent Grafts report also includes competitive depicting of the leading players in global Stent Grafts market, tempting investment scheme market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Key Players/Manufacturers Segment: Global Stent Grafts Market

Cook Medical
Bolton Medical
Lombard Medical
LifeTech Scientific
Merit Medical

Geographically, the global Stent Grafts market is designed for the following regional markets:

The industry research is disperse over the world which includes Stent Grafts market in North America (USA, Canada and Mexico), Stent Grafts market in Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Stent Grafts market in Europe (Germany, France, UK, Russia and Italy), Stent Grafts market in South America (Brazil, Argentina, Columbia etc.), Stent Grafts market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) and Other parts of the Globe. Due to increasing job opportunities in Asia-Pacific countries, China and India will show a tremendous development in the global Stent Grafts market. Use of advanced technology is holding the largest global Stent Grafts market share in North America. Adoption of Stent Grafts in the distinct fields in Europe will help to increase the expansion of Stent Grafts market globally.

The global Stent Grafts market is cut down into two segments each type and application.

Application Segment: Global Stent Grafts Market

Peripheral Stent Grafts
Aortic Stent Grafts

Type Segment: Global Stent Grafts Market

AAA Stent Grafts
TAA Stent Grafts

Gain Full Access of Global Stent Grafts Market Report with complete TOC at

At last, Brief Description of Each Chapter is provided

Reports Consists 15 Chapters in it which thoroughly exhibit the global Stent Grafts market 2017-2022.

Chapter 1, to features Stent Grafts Introduction, product purview, market synopsis, market opportunities of Stent Grafts, market peril, market motive;

Chapter 2, examines the top manufacturers in Stent Grafts, with sales, revenue, and price of Stent Grafts, in 2016 and 2017;

Chapter 3, exhibits the competitive situation among the Stent Grafts top manufacturing players, with sales, revenue, and market share in 2016 and 2017;

Chapter 4, explores regionwise analysis of global Stent Grafts market, with sales, revenue and market share, for each Stent Grafts region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9, scrutinizes the Stent Grafts key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, displays the market based on Stent Grafts type and application, with sales market share and Stent Grafts growth rate by type, application, from 2012 to 2017;

Chapter 12, deals with Stent Grafts market prognosis, by regions, type, and application, with Stent Grafts sales and revenue, from 2017 to 2022;

Chapter 13, 14 and 15, explores Stent Grafts industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source for Stent Grafts.

What Stent Grafts Market Research Report Provides:

The Industry study on global Stent Grafts market encompasses full in-depth analysis of the parent market and provides important changes in Stent Grafts dynamics. It also includes Former, on-going, and projected global Stent Grafts market analysis in terms of volume and value.

The industry report on Stent Grafts serves comprehensive information about Segmentation details of the market in Stent Grafts, Key strategies of major players, Market share analysis, and Stent Grafts Emerging segments and regional markets.

Along with the Assessment of niche industry developments, global Stent Grafts market report covers Testimonials to companies in order to fortify their foothold in the market.

Thus, the research study provides a comprehensive view of the global Stent Grafts market, offering market dimensions and evaluations for the period from 2017 to 2022, keeping in mind the aforementioned factors.

SOURCE talkherald

Medtronic Exclusive Reactive ATP(TM) Therapy Slows Progression of Atrial Fibrillation in Real-World Patient Population

DUBLIN and VIENNA- Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive ATP(TM) therapy slows the progression of AF in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA EUROPACE-CARDIOSTIM 2017.

An unusually fast or quivering rhythm in the heart’s upper chambers (atria), AF is a progressive disease that afflicts more than 33 million people worldwide.1 Common among patients with cardiac devices, AF impairs quality of life, and increases the risk of hospitalization, stroke and death. Reactive ATP (atrial-based antitachycardia pacing) is an advanced, painless pacing therapy found exclusively on Medtronic pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. It repeatedly sends pacing pulses to the atria during abnormally fast rhythms to restore the heart’s normal rhythm, thereby slowing the progression of AF.

The retrospective analysis assessed pacemaker, ICD and CRT device data from 8,798 patients followed by the Medtronic CareLink® remote monitoring system. Reactive ATP therapy was associated with a statistically significant decrease in AF events compared to a matched control group. Most notably, the Reactive ATP patient group experienced a 38 percent reduction in persistent AF events (lasting greater than seven days) (p<0.0001). This benefit was observed across patient age, sex, and device type.

“Atrial fibrillation can be a debilitating disease that imposes a significant burden upon the entire healthcare community – impacting patients, caregivers, providers and costs of care – especially as the disease progresses,” said Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at the University of Modena and Reggio Emilia, Italy. “These are the first real-world data on the clinical impact of Reactive ATP therapy and the first in patients with ICDs and CRT devices. These data have important implications for all device patients because of the high prevalence of AF and the correlation of disease progression to worsened patient outcomes.”

This study builds upon the MINERVA trial, the first randomized, controlled study of Reactive ATP. It found that Reactive ATP therapy significantly slowed AF disease progression in patients with pacemakers with the therapy, compared to those without it.2 Furthermore, Reactive ATP significantly reduced AF-related hospitalizations, emergency department visits and cardioversions, resulting in payer cost savings.2,3

“Physicians have been asking how the CareLink Network data can be leveraged to gain real-world insights into the benefits of our therapies,” said Rob Kowal, M.D., Ph.D., vice president and chief medical officer of the Cardiac Rhythm and Heart Failure Division at Medtronic. “This study does exactly that. It helps us understand how Reactive ATP impacts the burden of persistent atrial fibrillation in a larger and more varied group of patients than we might normally be able to study within the constraints of a controlled trial.”

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE GlobeNewswire

Medtronic scientist helped lead big changes in medical devices

Paul Skarstad

Paul Skarstad was a pioneering scientist at Medtronic who helped shrink the size of pacemakers and other medical devices by designing smaller, more powerful batteries that last much longer than their predecessors.

As a result of Skarstad’s groundbreaking research, the devices are now more reliable and comfortable to wear, and people can go as long as 15 years before needing a new one — a big improvement over the 1970s, when Skarstad joined what is now the world’s largest medical device company.

Skarstad, who retired from Medtronic in 2006, died May 15 from a heart attack while relaxing on the sofa at his Plymouth home of more than 40 years. He was 74.

“He was a really important person at Medtronic,” said Darrel Untereker, Medtronic’s vice president of technology. “Paul was the first to prove that a lot of things could be done. … Paul was a scientist’s scientist. He set standards for scientific rigor that are still in place today.”

Born in Grafton, N.D., Skarstad spent his teenage years working on the family farm and exploring the nearby countryside. He collected everything from rocks to butterflies, displaying an unquenchable curiosity that drove him throughout his life.

He studied chemistry at the University of Minnesota, where he met the woman who would become his wife. Both were in the orchestra.

“He played the violin, and I played the flute,” Marna Skarstad said. “Music was a theme for our whole life.”

After getting his Ph.D. in chemistry from Cornell University in 1972, Skarstad worked at the U.S. National Bureau of Standards for one year. He joined Medtronic in 1976.

Skarstad’s first major discoveries allowed Medtronic to increase the amount of current a medical device could draw from a battery, which was fairly limited at the time, colleagues recalled. He later developed the first power source for implantable defibrillators, which send a dose of electric current to the heart to correct abnormal rhythms.

Altogether, Skarstad and his research team collected 19 patents for their work, according to the U.S. Patent and Trademark Office. In his 30 years at Medtronic, Skarstad worked his way up through management and retired as senior director of energy systems, where he oversaw research and development on batteries and other power sources.

Colleagues say Skarstad was a demanding boss who pushed people to do their best, but at the same time was quick with a self-deprecating story to lighten the mood. He loved it when co-workers played pranks on him.

“He was a pretty awesome mentor,” said Medtronic manager Craig Schmidt, who worked with Skarstad for 17 years. “The first report I did for him underwent 21 revisions — my Ph.D. thesis underwent three revisions.”

Beyond his scientific pursuits, Skarstad was an adventurer who kayaked around the glaciers of Greenland and bicycled through the fjords of Norway. After he was diagnosed with Parkinson’s two years ago, he designed a training regimen that allowed him to continue bicycling 28 miles per day while still keeping his heart rate below 120 beats per minutes, as required by his doctor.

“He had a strong tremor in his right hand, but he didn’t let that stop him,” said Marna, who celebrated her 50th anniversary with Paul last August. “He loved the outdoors.”

In addition to his wife, Skarstad is survived by a son, Erik Skarstad; a daughter, Alida Skarstad Fischbach; five grandchildren and other close family members and friends. A memorial service will be held Saturday, at St. Philip the Deacon Lutheran Church, 17205 County Road 6 in Plymouth. Visitation will begin at 10 a.m.

SOURCE Startribune

Why Boston Scientific Continues To Invest In Endoscopy

We estimate that endoscopy constitutes around 20% of Boston Scientific‘s value. The company has made a number of acquisitions to strengthen its endoscopic product portfolio in recent years. So why is it doing so? The medical devices market has become incredibly competitive, and mergers and acquisitions have become a norm for companies looking to streamline their medical device portfolios. Additionally, Boston Scientific is facing strong pricing pressure from new entrants, especially in interventional cardiology. To put things in perspective, Johnson & Johnson has exited much of the cardiovascular medical device business, owing to erosion of growth opportunities amid severe competition. This has prompted Boston Scientific to look towards endoscopy as a growth driver.

Our price estimate of $27 for Boston Scientific is in line with the market.


Market Growth/Adoption Warrants Investment

The worldwide endoscopy devices market is expected to grow at nearly 6% annually, and exceed $40 billion by the end of our forecast period. There are multiple factors driving this growth including an aging population in the U.S., Europe and Japan, growing preference for minimally invasive surgery and a large number of use cases for endoscopic devices including surgical operations, internal diagnosis and anatomical observations. There has been a consistent increase in the incidence of cancer, gastrointestinal diseases, and other chronic diseases, which can be attributed to the aging population, growing incidence of obesity and lifestyle related factors. Additionally, the improvement in visualization and diagnosis technology, accompanied by higher awareness of advantages among medical professionals, is driving growth. The market is dominated by flexible endoscopes, and this is likely to continue because of the variety of conditions these endoscopes are used for. Boston Scientific has several products in this category.

Competitive Pressure In Other Areas

While the endoscopic devices market is quite competitive, Boston Scientific is facing even greater competitive pressure in some of its other key segments including interventional cardiology, pacemakers and defibrillators, which together account for nearly 50% of its valuation, according to our estimates. The company has seen its market share decline significantly in these areas and it makes sense for it to invest in the growing endoscopic device market.

The stent market is very competitive and has a number of competitors including Medtronic, Abbott Labs and others vying for market share. Additionally, Boston Scientific’s coronary stent sales, which are part of the interventional cardiology division, have declined due to issues surrounding the performance of some of its drug-eluting stents. Overall, many newer entrants have adopted aggressive pricing strategies and Boston Scientific has focused on cutting costs and differentiating its products in order to stay competitive.


Boston Scientific’s latest deep-brain stimulator earns CE mark

Boston Scientific picked up a CE mark for its rechargeable, MRI-compatible deep-brain stimulation (DBS) system for the treatment of movement disorder symptoms in Parkinson’s disease, dystonia and essential tremor.

While all three conditions are currently incurable, DBS is used to alleviate symptoms. An implanted device sends electrical impulses through lead wires to specific parts of the brain. The FDA has approved DBS as a treatment for the three conditions, but Boston Scientific’s DBS devices are unavailable in the U.S.

Boston Sci’s next-generation Vercise Gevia Deep Brain Stimulation System incorporates new programming software that enables physicians to see how stimulation will be distributed in the brain while they are personalizing therapy, according to a statement.

Traditionally, doctors will use imaging to determine the exact spot in the brain to target and use patient feedback to program stimulation. The software provides another source of information to help physicians optimize treatment.

“I now have the potential to better define the settings that can help patients because I have the ability to visualize their stimulation field while I am programming,” said Patricia Limousin, M.D., Ph.D., a neurologist at the National Hospital for Neurology and Neurosurgery in London, in the statement. “The Neural Navigator software brings together some of the most critical information I need to customize therapy for patients.”

While the FDA has approved DBS as a treatment for Parkinson’s, dystonia and essential tremor, Boston Scientific has yet to crack that market. Its competitors, St. Jude Medical and Medtronic, both sell DBS systems in the U.S.

SOURCE Fierce Biotech

Boston Scientific to invest €17 million in new Galway endoscopy facility

Boston Scientific’s announcement that it is to invest €17 million in its new Endoscopy design facility in Galway, “reaffirms Ireland’s position as one of the international leaders in the medtech industry”.

This is the view of the Minister for Gaeltacht Affairs and Natural Resources and Fine Gael Galway West TD Seán Kyne, who was speaking at yesterday’s launch by Boston Scientific of its new RoadRunner endoscopy design facility in Galway. The company also announced it had committed to investing €17 million by 2020 in both endoscopy research and in the new facility.

The RoadRunner design process can deliver novel medical devices within six months, while the facility will allow more than 300 international physicians each year to promote collaboration and the rapid development of metal stents, devices used in the management of gastrointestinal obstructions, such as in the bowel or biliary tract. Through collaboration between engineers and physicians, the RoadRunner process will seek to ensure devices are developed more rapidly, while also ensuring they meet patient and physician needs.

Using the RoadRunner process, Boston Scientific has already developed two novel enteral stents – devices inserted into the duodenum (small intestine ) and colon. This includes the WallFlex soft enteral stent, which is easier for physicians to use in clinical practice, and which also reduces patient discomfort. The stent was also developed within six months, regarded as a significant reduction in the time usually taken to develop such devices.

“The investment reaffirms Ireland’s position as one of the international leaders in the medtech industry,” said Dep Kyne. “As the largest medical devices employer in Ireland, Boston Scientific has a reputation as a significant and valued employer in Galway; while globally, the products manufactured in Ireland positively impact human health across the world. I welcome this announcement and the Government and its agencies will continue to nurture our important relationship with Boston Scientific into the future.”

Art Butcher, senior vice president, endoscopy, Boston Scientific, said the company’s “investment in Galway signifies our commitment to ensuring the long-term sustainability of innovation here and to investing in the technology of the future”. He said he was “excited by the early successes” coming out of RoadRunner, which have “allowed us to deliver rapid innovation, incorporating physician feedback, to create meaningful advances for patients who need gastrointestinal stents.

Darragh Colgan, Boston Scientific vice president of process development, said that through the RoadRunner facility, “our engineers will gather real time feedback from international clinicians” to inform innovation and design at every stage in the development of a stent. He said this would “significantly reduce the time it takes” for a device to make its transition “from bench to bedside”.

Some 40 international research and clinical experts attended Wednesday’s launch, which also marked the 20th anniversary of Boston Scientific’s European Innovation Centre in Galway, which has produced more than three million devices in total.

The Boston Scientific site in Galway was first established in 1994 and employs more than 3,000 people. It develops devices across several therapeutic areas aside from endoscopy, including peripheral artery disease and aortic valve disease.

SOURCE Galway Advertiser

Edwards Lifesciences (EW) SAPIEN 3 THV Gets FDA Approval

Medical equipment major Edwards Lifesciences Corporation EW recently announced the receipt of FDA approval for aortic and mitral valve-in-valve procedures using SAPIEN 3 transcatheter heart valve (THV). This expanded indication represents the first appr
oval for the SAPIEN 3 valve in the U.S. for bioprosthetic valve replacement in aortic and mitral patients.

Basically, SAPIEN 3 is an artificial valve which falls under Edwards Lifesciences’ THV segment. This segment includes technologies designed to treat heart valve diseases using catheter-based appr
oaches as opposed to open surgical techniques.

The latest indication expansion was based on data collected from the Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. The results displayed that patients can be safely treated with SAPIEN 3 valve for bioprosthetic mitral valve replacement through valve-in-valve procedure rather than subsequent high-risk open heart surgery.

In the above mentioned procedure, the new transcatheter valve is inserted tightly within the failed prosthetic valve, pushing the old valve leaflets aside.

To be noted, Edwards Lifescience’s SAPIEN 3 valve got FDA approval in 2015 for severe, symptomatic aortic stenosis patients at high risk for open heart surgery. In 2016, it received approval for the treatment of patients who are at intermediate risk for open-heart surgery.

Taking into consideration the huge growth potential of the THV market, the recent FDA approval for SAPIEN 3 Valve is a strategic fit. As per Persistence Market Research report, the global heart valve repair and replacement market is projected to be worth $3,767.0 million in 2020 at a CAGR of 8.7%.

Of late, Edward Lifesciences has witnessed multiple developments in its THV segment. Management released positive patient outcomes of SAPIEN 3 valve including high survival rates and low rates of stroke and paravalvular leak. In another study, Edwards Lifesciences’ CENTERA valve displayed favorable results for transcatheter aortic valve replacement (TAVR) patients.

Meanwhile, over the last one month, Edwards Lifesciences has been trading above the Zacks categorized Medical – Instruments industry. The company has gained 6.3%, compared to the 4.9% gain of the broader industry. We believe that compelling clinical evidences and regulatory approvals at the THV segment will further boost share price in the near future.

SOURCE nasdaq

Cook Pharmica named Facility of the Year

Cook Pharmica named Facility of the Year

Cook Pharmica won the ISPE “Facility of the Year Award” (FOYA) for the “Flexible Filling Line” (FFL). The project was executed together with Optima Pharma as a partner for filling, closing and isolator technologies.

The FFL consists of the OPTIMA MultiUse Filler, which was designed and developed especially for Cook’s needs. The prize was awarded by the Internal Society for Pharmaceutical Engineering (ISPE) and fell under the category “Equipment Innovation.”

Cook is a privately held contract development and manufacturing organization (CDMO) that provides biopharmaceutical companies with a one-source, one-location model for development, clinical or commercial cell culture manufacturing, formulation, parenteral product manufacturing and packaging. Bloomington, IN-based Cook Pharmica is a wholly owned subsidiary of the Cook Group, which includes Cook Medical, a privately held medical device manufacturer.

A special feature of the FFL is the ability to process different types of containers including vials, cartridges and syringes on one machine, instead of having three separate lines as in the past. Flexibility can also be seen in the dosing systems (peristaltic pumps and time pressure) and the container sizes that can be processed on the line. The implementation of robotics and automation to maximize flexibility makes it the “first of its kind,” according to the selection committee.

The line is implemented by Cook Pharmica for production and clinical manufacturing. Dosing systems help in product savings, with several product paths available to make the best use out of filling, closing and freeze-drying functions. The line is designed to process oxygen and light-sensitive products.

ISPE is a not-for-profit association serving its members by leading scientific, technical and regulatory advancement throughout the pharmaceutical lifecycle. It is committed to the advancement of the educational and technical efficiency of its members.

SOURCE Healthcare Packaging

St. Jude Medical May Establish ABT as a Key Medical Device Player

On January 4, 2017, Abbott Laboratories (ABT) announced the completion of its acquisition of St. Jude Medical. The deal is expected to catapult Abbott to a dominant position in all areas of the cardiovascular device market, currently valued at ~$30 billion.

St. Jude Medical has added a strong portfolio that consists of devices required for treating atrial fibrillation, structural heart issues, chronic pain, and heart failure that complement Abbott Laboratories’ portfolio in the coronary intervention and mitral valve disease areas. To know more about the deal’s synergies, read Rationale for the St. Jude Medical-Abbott Merger Transaction.

St. Jude Medical May Establish ABT as a Key Medical Device Player

In 1Q17, Abbott Laboratories divested St. Jude Medical’s vascular closure business as well as its medical optics business. Besides generating excess funds, these divestitures have also helped Abbott to reduce antitrust issues related to the deal.

In the event the acquisition of St. Jude Medical manages to position Abbott Laboratories as a leader in the medical device space, its stock price may see a boost, as could the price of the SPDR S&P Dividend ETF (SDY). Abbott Laboratories makes up ~0.98% of SDY’s total portfolio holdings.

The above diagram shows the position of Abbott Laboratories in various areas of the cardiovascular segment after its complete integration of St. Jude Medical. This strategic acquisition is expected to enable Abbott Laboratories to pose strong competition to other medical device players such as Medtronic (MDT), Thermo Fisher Scientific (TMO), and Boston Scientific (BSX).

FDA warning letter

On April 12, 2017, the FDA issued a warning letter to Abbott Laboratories related to its adulteration of Unify Fortify, Assura implantable cardioverter defibrillators, Merlin@home Transmitters, and cardiac resynchronization therapy defibrillators at St. Jude’s Sylmar facility in California. Since Abbott is well-versed in the requirements of good manufacturing practices, the company is confident that it can remedy these issues.

SOURCE Market Realist

Medtronic, GlaxoSmithKline team up in $40M equity deal for back-pain startup

Medtronic has joined in a $40 million round of equity financing for Saluda Medical, a med-tech company with operations in the Twin Cities.

Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses. The Australia-based company expanded into the United States two years ago, starting a seven-employee clinical research team in Bloomington, Minn.

The company plans to expand its Twin Cities operation following the round of funding, Saluda Medical Senior Vice President Dan Brounstein said in an email. “It is the place to start a medical device company and we are dedicated to continued growth.”

Action Potential Venture Capital, a venture arm of GlaxoSmithKline, led the round of funding. Medtronic was a return investor.

Saluda pans to put its recent round of funding, which totaled $53 million in Australian dollars, toward a U.S. clinical trial. It is also seeking regulatory approvals to sell its product, called the Evoke Spinal Cord Stimulator, in Europe and Australia.

Medtronic and other large medical-device makers already sell neurostimulators that treat pain and other conditions. Saluda’s device aims to distinguish itself from competing products by acting as a closed-loop system, adjusting the amount of electricity it delivers based on how a patient’s neural tissue responds to stimulation. Other devices require that a patient manually adjust stimulation levels.

Research and development of technology that can sense and respond to brain activity has been a longtime focus for Medtronic. The company’s efforts include building a so-called “brain radio.” Meanwhile, California-based NeruoPace Inc. makes a closed-loop stimulator that treats epilepsy.

Dublin-based Medtronic’s operational headquarters are in Fridley.

SOURCE Bizjournals